Market Cap | 664.49M | P/E | - | EPS this Y | 10.00% | Ern Qtrly Grth | - |
Income | -41.53M | Forward P/E | -13.05 | EPS next Y | -16.70% | 50D Avg Chg | -4.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -14.00% |
Dividend | N/A | Price/Book | 4.54 | EPS next 5Y | - | 52W High Chg | -46.00% |
Recommedations | 2.00 | Quick Ratio | 11.95 | Shares Outstanding | 84.80M | 52W Low Chg | 10.00% |
Insider Own | 3.05% | ROA | -20.43% | Shares Float | 82.21M | Beta | 0.62 |
Inst Own | 31.83% | ROE | -30.03% | Shares Shorted/Prior | 19.61M/19.75M | Price | 8.22 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 877,169 | Target Price | 35.47 |
Oper. Margin | - | Earnings Date | Nov 25 | Volume | 616,765 | Change | 0.86% |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
HC Wainwright & Co. | Buy | Aug 1, 24 |
EF Hutton | Buy | Jul 29, 24 |
EF Hutton | Buy | Jul 22, 24 |
HC Wainwright & Co. | Buy | Jun 11, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Jan 3, 24 |
HC Wainwright & Co. | Buy | Nov 28, 23 |
HC Wainwright & Co. | Buy | Aug 8, 23 |
HC Wainwright & Co. | Buy | Jul 20, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
MISSLING CHRISTOPHER U | President and CEO President and CEO | Jun 28 | Sell | 7.98 | 268,000 | 2,138,640 | 1,018,210 | 06/30/23 |
MISSLING CHRISTOPHER U | President and CEO President and CEO | Jun 28 | Option | 1.6 | 500,000 | 800,000 | 1,250,210 | 06/30/23 |
Skarpelos Athanasios | Director Director | May 25 | Option | 0.92 | 50,000 | 46,000 | 1,356,458 | 05/27/22 |
Skarpelos Athanasios | Director Director | May 25 | Sell | 9.06 | 50,000 | 453,000 | 1,306,458 | 05/27/22 |
MISSLING CHRISTOPHER U | President and CEO President and CEO | Jul 01 | Option | 1.32 | 51,620 | 68,138 | 1,069,830 | 07/01/21 |
MISSLING CHRISTOPHER U | President and CEO President and CEO | Jul 01 | Sell | 26 | 51,620 | 1,342,120 | 1,018,210 | 07/01/21 |
Boenisch Sandra | PFO and Treasurer PFO and Treasurer | Jul 01 | Option | 4.96 | 166,696 | 826,812 | 189,659 | 07/01/21 |
Boenisch Sandra | PFO and Treasurer PFO and Treasurer | Jul 01 | Sell | 26.53 | 166,696 | 4,422,445 | 22,963 | 07/01/21 |
FAVUS ELLIOT | Director Director | May 25 | Option | 4.12 | 145,000 | 597,400 | 145,000 | 05/25/21 |
FAVUS ELLIOT | Director Director | May 25 | Sell | 11.7 | 145,000 | 1,696,500 | 05/25/21 | |
FAVUS ELLIOT | Director Director | Feb 26 | Option | 2.93 | 145,500 | 426,315 | 145,000 | 02/26/21 |
FAVUS ELLIOT | Director Director | Feb 26 | Sell | 12.66 | 145,500 | 1,842,030 | 02/26/21 | |
Donhauser Peter D.O. | Director Director | Feb 23 | Buy | 12.8 | 1,165 | 14,912 | 1,165 | 02/23/21 |